Related Experiment Video
Updated: May 16, 2025
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Plasma miRNA Biomarker Signatures in Parkinsonian Syndromes
Stylianos Ravanidis1, Anastasia Bougea1,2, Christos Koros2
1Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527, Athens, Greece.
Abstract:
Diagnosing atypical parkinsonian syndromes (APS) remains challenging due to overlapping clinical features and limited diagnostic tools. Brain-enriched microRNAs (miRNAs), which regulate neuronal development and function, are detectable in plasma and could serve as molecular biomarkers. This prospective study aimed to identify plasma brain-enriched miRNAs that can distinguish APS and elucidate affected molecular pathways. Reverse transcription-quantitative PCR (RT-qPCR) was performed on plasma samples from patients with idiopathic Parkinson's disease (iPD), multiple system atrophy (MSA), including the cerebellar subtype (MSA-C) and the parkinsonian subtype (MSA-P), progressive supranuclear palsy (PSP), and healthy controls. MiRNA expression analysis revealed distinct molecular fingerprints for each parkinsonian syndrome, with opposite trends between MSA and iPD compared to controls, suggesting distinct pathogenic mechanisms. Most dysregulated miRNAs clustered at chromosome (Chr)14q32 and shared binding sites for CREB1, CEBPB, and MAZ transcription factors. Pathway analysis revealed enrichment in prion diseases, Hippo signaling, TGF-beta signaling, and FoxO signaling pathways.
Insights
Plasma microRNAs (miRNAs) show distinct patterns in atypical parkinsonian syndromes (APS), offering potential biomarkers for diagnosis. These brain-enriched molecules may help differentiate conditions like Parkinson's disease and multiple system atrophy.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Diagnosing atypical parkinsonian syndromes (APS) is difficult due to similar symptoms and lack of specific tests.
- Brain-enriched microRNAs (miRNAs) in plasma are potential biomarkers for neurological disorders.
Purpose of the Study:
- To identify plasma brain-enriched miRNAs that differentiate APS.
- To explore the molecular pathways affected in these conditions.
Main Methods:
- Prospective study analyzing plasma samples from patients with idiopathic Parkinson's disease (iPD), multiple system atrophy (MSA subtypes), progressive supranuclear palsy (PSP), and controls.
- Reverse transcription-quantitative PCR (RT-qPCR) for miRNA expression analysis.
- Bioinformatic pathway analysis.
Main Results:
- Distinct plasma miRNA expression profiles were found for iPD, MSA, and PSP.
- Opposite miRNA expression trends between MSA and iPD compared to controls suggest different disease mechanisms.
- Dysregulated miRNAs were enriched at chromosome 14q32 and targeted specific transcription factors.
- Enriched pathways included prion diseases, Hippo signaling, TGF-beta signaling, and FoxO signaling.
Conclusions:
- Plasma brain-enriched miRNAs can serve as diagnostic biomarkers for distinguishing between atypical parkinsonian syndromes.
- These findings provide insights into the distinct molecular pathologies underlying different parkinsonian disorders.
More Related Videos
Related Concept Videos
01:37Neural Regulation
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview